Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

Journal of Clinical Endocrinology and Metabolism

Volumn 79, Issue 1, 1994, Pages 145-151

  Morange, I ^a   Boisvilliers, F De ^a   Chanson, P ^a   Lucas, B ^a   Dewailly, D ^a   Catus, F ^b   Thomas, F ^b   Jaquet, P ^a  

^a Department of Endocrinology and CNRS U 994 ^*  (France)

^b IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; FEMALE; GLUCOSE HOMEOSTASIS; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS TUMOR; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PHARMACEUTICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION;

ACROMEGALY; ADENOMA; ADULT; AGED; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOSE TOLERANCE TEST; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 0028222326     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.79.1.8027218     Document Type: Article

References (21)

1. Vance ML, Harris AG. 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med. 151:1573-1578.
2. Lamberts SWJ, Uitterlinden P, Vershoor L, Van Dongen KJ, del Pozo E. 1985 Long-term treatment of acromegaly with the somatostatin anolog SMS 201-995. N Engl J Med. 313:1576-1580.
3. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. 1988 Treatment of acromegaly with the long-acting somatostatin analog SMS 201- 995. J Clin Endocrinol Metab. 66:16-23.
4. Chiodini PG, Cozzi R, Dallabonzana D, et al. 1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab. 64:447-453.
5. Quabbe HJ, Plockinger U. 1989 Dose-response study and longterm effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab. 68:873-880.
6. Ho KY, Weissberger AJ, Marbach P, Lazarus L. 1990 Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med. 112:173-181.
7. Sassolas G, Harris AG, James-Deidier A, et al. 1990 Long-term effect of incremental doses of the somatostatin analog SMS 201995 in 58 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
8. Shi YF, Harris AG, Zhui XF, et al. 1990 Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in 10 acromegalic patients. Clin Endocrinol (Oxf). 32:695-699.
9. Barkan AL. 1989 Acromegaly. Diagnosis and therapy. Endocrinol Metab Clin North Am. 18:277-310.
10. Sassolas G, Khalfallah Y, Chayvialle JA, et al. 1989 Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin and digestive peptides in normal men. J Clin Endocrinol Metab. 68:239-246.
11. Heron I, Thomas F, Dero M, et al. 1993 Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab. 76:721-727.
12. Chabert Orsini V, Simonin G, Brue T, Conte-Devolx B, Carayon P. 1993 Dosage sérique de l'hormone de croissance humaine. Comparaison de six trousses de dosage. Ann Endocrinol (Paris). 53:153-157.
13. Lamberts SWJ. 1988 The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 9:417-438.
14. James RA, White MC, Moller N, et al. 1989 Continuous infusion of sandostatin in acromegaly. Lancet. 2:1083-1087.
15. Tauber JP, Babin Th, Tauber MT, et al. 1989 Long-term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 68:917-923.
16. Christensen C, Weeke J, Orskov H, et al. 1987 Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf). 27:297-306.
17. Timsit J, Chanson P, Larger E, et al. 1987 The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analog (SMS 201-995) on the diurnal GH profile in acromegaly. Acta Endocrinol (Copenh). 116:108-112.
18. Heron I, Thomas F, Dero M, et al. 1993 Traitement de l'acromégalie par une forme à libération prolongée du lanreotide. Presse Med. 22:526-531.
19. Wass JA. 1990 Octreotide treatment of acromegaly. Horm Res. 33:1-12.
20. Ducasse MCR, Tauber JP, Tourre A, et al. 1987 Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 65:1042-1046.
21. Kuhn JM, Basin C, Mollard M, De Rouge B, Schatz B, Wolf LM. 1992 Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur J Clin Invest. 22:793-799.